Table 2.
Mean drug deposition and aerosolization performance of CC1 with resin or metal 3D rod arrays and with the PTFE coated capsule and inhaler tested at a 4 kPa pressure drop (equivalent to 50 L/min for each inhaler). Coefficient of variation (%) is shown in parenthesis [n=3].
| Description | CC1-3D | CC1-3Dm | CC1-3Dm-PTFE |
|---|---|---|---|
| Emitted (%)* | 63.8 (3.0) | 64.7 (2.3) | 81.4 (2.7)** |
| Capsule retention (%)* | 14.1 (9.0) | 16.2 (4.1) | 7.3 (14.2)** |
| Capsule chamber retention (%)* | 8.8 (15.3) | 8.8 (11.0) | 2.2 (25.4)** |
| Mouthpiece retention (%)* | 13.2 (2.7) | 10.2 (3.6)** | 9.1 (15.9)** |
| FPF<5µm/ED (%) | 93.9 (0.4) | 94.5 (0.9) | 92.7 (1.3) |
| FPF<1µm/ED (%)* | 32.2 (3.2) | 37.3 (2.6)** | 36.8 (2.3)** |
| MMAD (µm)* | 1.44 (1.96) | 1.30 (1.74)** | 1.30 (0.97)** |
P<0.05 significant effect of uncoated devices built with resin and metal 3D arrays and PTFE coated inhaler device with metal 3D array on % emitted, capsule, capsule chamber % mouthpiece retentions, FPF<1µm/ED and MMAD (one-way ANOVA).
P<0.05 significant effect of % emitted, capsule, capsule chamber & mouthpiece retentions, FPF<1µm/ED and MMAD compared to CC1-3D with resin rod array (post-hoc Tukey).
Batch-2 EEG formulation combination particles generated by Büchi Nano Spray Dryer (B-90).